![Janet L. Smart](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Janet L. Smart
Keine laufenden Positionen mehr
Karriereverlauf von Janet L. Smart
Ehemalige bekannte Positionen von Janet L. Smart
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Anchor Therapeutics, Inc.
![]() Anchor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Anchor Therapeutics, Inc. designs and develops peptide modulators of G protein-coupled receptors (GPCRs). The firm engages in developing and licensing pepducin technology as a research tool for drug development; and pepducin drug candidates and novel molecules that are intended for targeting GPCR to allosterically modulate GPCR signaling. Its pepducin lipopeptides are designed to allosterically modulate internal cell signaling via specific interactions with intracellular GPCR domains. The company also focuses on developing its pepducin technology for creating new treatment options for regenerative medicine, diabetes, inflammation, and cancer. Anchor Therapeutics was founded by Thomas J. McMurry and Athan Kuliopulos in 2006 and is headquartered in Cambridge, MA. | General Counsel | 01.08.2010 | 01.10.2011 |
PROTEOSTASIS THERAPEUTICS, INC. | General Counsel | - | - |
Corporate Officer/Principal | 01.01.2011 | - | |
Unternehmenssekretär | - | - |
Ausbildung von Janet L. Smart
University of New Hampshire School of Law | Graduate Degree |
Northeastern University | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 5 |
Operativ
General Counsel | 2 |
Graduate Degree | 2 |
Corporate Officer/Principal | 1 |
Sektoral
Health Technology | 3 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
Proteostasis Therapeutics, Inc.
![]() Proteostasis Therapeutics, Inc. BiotechnologyHealth Technology Proteostasis Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It engages in the discovery and development of novel therapeutics to treat cystic fibrosis (CF) and other diseases caused by an imbalance in the proteostasis network. The company was founded by William Balch, Jeffery W. Kelly, Andrew Dillin, Richard I. Morimoto, Alfred Lewis Goldberg, Daniel Finley, Christopher T. Walsh, and Randall W. King in 2006 and is headquartered in Boston, MA. | Health Technology |
Anchor Therapeutics, Inc.
![]() Anchor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Anchor Therapeutics, Inc. designs and develops peptide modulators of G protein-coupled receptors (GPCRs). The firm engages in developing and licensing pepducin technology as a research tool for drug development; and pepducin drug candidates and novel molecules that are intended for targeting GPCR to allosterically modulate GPCR signaling. Its pepducin lipopeptides are designed to allosterically modulate internal cell signaling via specific interactions with intracellular GPCR domains. The company also focuses on developing its pepducin technology for creating new treatment options for regenerative medicine, diabetes, inflammation, and cancer. Anchor Therapeutics was founded by Thomas J. McMurry and Athan Kuliopulos in 2006 and is headquartered in Cambridge, MA. | Health Technology |
- Börse
- Insiders
- Janet L. Smart
- Erfahrung